Overview of Cancer Genetics The Role of Cancer
- Slides: 37
Overview of Cancer Genetics The Role of Cancer Genetics in Precision Medicine April 17, 2018 / May 1, 2018 Vanessa Manso / Matthew Share, MS Licensed / Certified Genetic Counselor William G. Rohrer Cancer Genetics Program
Objectives • Identify the best practices for referring patients for genetic counseling • Discuss the key components of genetic assessment and testing • Describe current approaches to genetic testing for hereditary cancer syndromes • Identify potential benefits and limitations of the multigene panel testing approach for hereditary cancer • Discuss the implications, risks, and benefits of genetic testing for the individual and their family • Recognize key features of major genetic syndromes
Most Cancers are Sporadic • Sporadic (~70%) – Environmental exposures / random chance • Familial (~20%) – Shared environmental exposures – Similar genetic background • Hereditary (~10%) – Inherited genetic mutation increased risk Image from http: //publications. nigms. nih. gov/thenewgenetics/chapter 1. html
Family History Features Suggestive of Hereditary Cancer Syndromes Cancer in 2+ relatives • Multiple generations • Same side of the family Younger age @ cancer diagnosis Multiple primary cancers • Includes bilateral Less common cancer types • Ovarian cancer • Breast cancer in a man • Paraganglioma • Medullary thyroid cancer Absence of typical environmental risk factors Cancer with certain pathologic characteristics • “Triple negative” breast cancer • Cancer cells with genetic instability or abnormal staining Ancestry w/ higher incidence of mutations in hereditary cancer syndrome genes • Ashkenazi Jewish ancestry & BRCA 1, BRCA 2 Blood relative(s) with a known mutation
Sporadic Familial Hereditary Bilateral Breast @41 & 52 Breast @71 Breast @57 Breast @43 Breast @ 80 Breast @63 Breast @37
Key Components of Genetic Assessment and Testing • Medical & family history obtained / assessed • Education regarding hereditary cancer • Informed consent: explain clinical and familial implications of genetic testing and other diagnostic studies • Healthy tissue sample (blood, saliva, cheek cells) obtained if proceeding with testing https: //www. nsgc. org/p/cm/ld/fid=18#scope
Genetic Testing Practices Syndrome- or gene-specific testing (1990’s-present) • Typically single gene or single syndrome testing – i. e. BRCA 1 / BRCA 2; Lynch syndrome; CDH 1; etc. • Single-site testing for a known mutation Multi-gene testing (“panel testing”; 2013 -present) • Variable number of genes tested • Pan-cancer versus targeted cancer gene panels • Panel based on level of known cancer risk – High / moderate / “increased” risk levels http: //www. cancer. gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq#link/_1320
The Majority of Breast Cancers Do Not Have an Identifiable Germline Mutation
The Majority of Ovarian Cancers Do Not Have an Identifiable Germline Mutation
When to Refer for Further Genetic Risk Evaluation: Breast & Ovarian • Breast cancer diagnosed ≤ 50 years • Ashkenazi Jewish ancestry and breast/ovarian (or pancreatic) cancer • Triple negative breast cancer ≤ 60 • Multiple primary cancers • Breast cancer in a male • Ovarian cancer at any age • Family history and/or known familial mutation NCCN version 1. 2018 “Genetic/Familial High Risk Assessment: Breast and Ovarian”; www. nccn. org
http: //www. breastlink. com/wp-content/uploads/2015/04/Nimmi-S-Kapoor-MD-Genetic-Testing-American-Society-Breast-Surgeons. pdf
Hereditary Breast Cancer Genes High Risk Moderate Risk Increased Risk BRCA 1 ATM BARD 1 BRCA 2 CHEK 2 BRIP 1 CDH 1 PALB 2 NBN PTEN RAD 50 STK 11 RAD 51 C TP 53 RAD 51 D others… Lynch syndrome genes (MLH 1, MSH 2, MSH 6, PMS 2, EPCAM) **possible increased risk of breast cancer for carriers**
The Majority of Colorectal Cancers Do Not Have an Identifiable Germline Mutation
When to Refer for Further Genetic Risk Evaluation: Colorectal Cancer (CRC) • • • CRC diagnosed ≤ 50 Amsterdam and Bethesda Criteria Lynch screen: IHC/MSI Lifetime polyp count Family history Known familial mutation NCCN version 3. 2017 “Genetic/Familial High Risk Assessment: Colorectal”; www. nccn. org
Hereditary CRC Syndromes • Lynch syndrome (Hereditary nonpolyposis colorectal cancer)- MLH 1, MSH 2, MSH 6, PMS 2, EPCAM – Colon, uterine, stomach, other cancer risks • Familial adenomatous polyposis (FAP)- APC – Colon polyps (100+) – Extracolonic findings: CHRPE, extra teeth, desmoids • MUTYH-associated polyposis (MAP)- MUTYH – Colon polyps (0 -100), duodenal cancer, duodenal polyps NCCN version 3. 2017 “Genetic/Familial High Risk Assessment: Colorectal”; www. nccn. org
Hereditary Gastric Cancer Syndromes • Hereditary diffuse gastric cancer: CDH 1 (possibly CTNNA 1) – Gastric cancer (up to 70 -80%); lobular breast cancer (40 -50%) • Gastric cancer: Lynch syndrome, Juvenile polyposis syndrome (BMPR 1 A, SMAD 4), Peutz -Jeghers syndrome (STK 11), APC • Gastrointestinal stromal tumor (GIST): KIT, NF 1, PDGFRA, SDHA/B/C/D https: //www. cancer. net/cancer-types/hereditary-diffuse-gastric-cancer NCCN version 5. 2017 “Gastric Cancer”; www. nccn. org
Potential Benefits of Multi-Gene Testing (versus traditional sequential gene testing) • Higher mutation detection rate especially for patients who do not meet specific personal or family history criteria • Lower likelihood of “uninformative” negative results • Often more cost- and time-efficient • May find a mutation in more than one gene NCCN version 1. 2018 “Genetic/Familial High Risk Assessment: Breast and Ovarian”; www. nccn. org
Considerations of Multi-Gene Testing • Which test (# genes? ) or laboratory to choose? – Increased risk for variant result – Faster / cheaper ≠ better • Limited data re: cancer risks associated with some genes • Potential lack of clear medical management guidelines for mutation carriers • Challenges in making medical management recommendations if a patient carries mutations in multiple genes • Potential added TAT for larger panels NCCN version 1. 2018 “Genetic/Familial High Risk Assessment: Breast and Ovarian”; www. nccn. org
Possible Results of Genetic Testing • Positive – – “Mutation” “Pathogenic variant” “Deleterious variant” “Likely pathogenic/deleterious variant” • Negative • Variant of uncertain/unknown significance
Pathogenic mutation Slide for professional use from Myriad Genetic Laboratories https: //new. myriadpro. com/products/myriad-myrisk/patient-education/ Use of this image does not imply endorsement.
Positive Test Result Cancer risk(s) increased due to pathogenic hereditary gene mutation • Cancer treatment decisions (if applicable) – Result may influence surgical decisions, chemotherapy options, clinical trial eligibility • Cancer screening and risk reduction options – Additional imaging? More frequent clinical exams? – Surgery? Chemoprevention? Lifestyle changes? • Information for the family – A “diagnosis” for the family – Testing of relatives with / without cancer for the known mutation • May or may not influence clinical care and management
Negative/Uncertain Test Result Cancer risk(s) may still be increased based on personal risk factors and/or family history • Cancer treatment decisions (if applicable) – Not impacted by result • Cancer screening and risk reduction options – Based on personal and family history • Information for the family – A negative/variant result does not eliminate the possibility of hereditary cancer in the family – Other family members may still wish to consider genetic testing
What is a Variant of Uncertain Significance? • Alteration in a gene with limited and/or conflicting evidence regarding pathogenicity • Classification system – – – AA biochemical similarities Presence/absence in healthy individuals Presence in individuals with X-related cancers Prediction algorithms: Poly. Phen and SIFT Internal data *Occasional variant classification studies through laboratory*
Emerging Evidence Testing • Single nucleotide polymorphisms (SNP) – Small single-base changes in the genetic code that collectively may increase cancer risk – Polygenic risk score combined with risk models to calculate new risk estimate • Considerations: – How to use results clinically is not yet clear – Labs will not re calculate score as information changes – Some opt out, others opt in, rapidly evolving field
Tumor vs. Germline Testing • One is not a substitute for the other! • Tumor genetic testing may detect a mutation that is also in the germline • A tumor “mutation” might be considered a germline “variant of uncertain significance” • May do germline testing to follow up on a mutation found via tumor testing – dependent on the gene and the personal / family history – targeted to the mutation or to include full gene analysis +/other genes
Slide for professional use from Myriad Genetic Laboratories https: //new. myriadpro. com/products/myriad-myrisk/patient-education/ Use of this image does not imply endorsement.
DTC testing- 23 and. Me https: //www. 23 andme. com/dna-health-ancestry/
DTC testing- 23 and. Me • No physician order necessary • Consumers “opt-in” to receive this part of result • Not relevant result for general population (non. AJ) • Not full BRCA 1/BRCA 2 analysis • No other hereditary breast cancer genes studied • Positive* result • Negative result - concerns – may lead to false sense of security re: cancer risk – may deter individuals from seeking clinical genetic evaluation
Summary • Several reasons for a patient to be referred to genetics – Personal diagnosis, family history, screening tests, less common cancer types • The scope of testing can vary • Genetic testing is negative more often than not • Identification of a genetic syndrome / mutation can have major impact on patients and families
Case #1 Prostate @ 43 BRCA 2: breast (male and female), ovarian, prostate, pancreatic, melanoma 45 43 Breast @ 42 9 -gene breast cancer panel: BRCA 2+ 20 Single site testing: BRCA 2+ Single site testing: BRCA 2 - Breast @ 72 38 Single site testing: BRCA 2+ 40 Single site testing: BRCA 2+ 18 Single site testing: BRCA 2 - Ancestry: Maternal- SE Asian, Paternal- Irish, non-Jewish
Case #2 MLH 1: colon, uterine, gastric, ovarian, pancreatic, etc. 59 62 Colon @45 Genetic testing 2014 9 gene gyn cancer panel: MLH 1+ 34 Prostate @ 72 Colon @49 Ovarian @60 58 Uterine Colon @52 @48 & 58 57 52 Single site testing: MLH 1+ 28 6 Single site testing: MLH 1+ Single site testing: MLH 1 - Ancestry: African, non-Jewish
Case #3 63 CDH 1: diffuse gastric cancer, lobular breast cancer, signet ring colon cancer 23 Gastric @23 Signet ring features Genetic Testing: CDH 1+ Lobular breast @ 51 31 Single site testing: CDH 1+ 20 Single site testing: CDH 1+ P Ancestry: Maternal & Paternal- Irish, Non-Jewish
Cancer Genetics Program Practice Locations 2 Cooper Plaza, Camden 900 Centennial Blvd, Voorhees 100 Salem Drive, Willingboro Locations for Inspira patients: Vineland, Mickleton, Mullica Hill
Cancer Genetics Program Team Oncologists Generosa Grana, MD (Program Director) Christina Brus, MD Alexandre Hageboutros, MD A. Kamel Abou Hussein, MD Pallav Mehta, MD Jamin Morrison, MD Kumar Rajagopalan, MD Kanu Sharan, MD Robert Somer, MD Christian Squillante, MD Preeti Sudheendra, MD Advanced Practice Nurses (APNs) Jennifer Bonafiglia, APN-C Phyllis Duda, APN-C Kristi Kennedy, APN-C Helen Nichter, APN-C Evelyn Robles-Rodriguez, APN-C Genetic Counselors Brooke Levin, MS, LCGC Vanessa Manso, MS, LCGC Kristin Mattie, MS, LCGC Matthew Share, MS, LCGC Jennie Stone, MS, LCGC Program Staff Manager Evelyn Robles-Rodriguez, RN, MSN, APN, AOCN Administrative Coordinator Brandi Ford, CCMA, AAS (Camden) Medical Assistant Myra Salcedo, RMA (Camden)
Cancer Genetics Program Genetic Counselors L to R: Kristin Mattie, Vanessa Manso, Matthew Share, Jennie Stone, Brooke Levin
- Web role in azure
- Role making krappmann
- Statuses and their related roles determine
- Cách giải mật thư tọa độ
- Từ ngữ thể hiện lòng nhân hậu
- Tư thế ngồi viết
- Trời xanh đây là của chúng ta thể thơ
- V. c c
- Voi kéo gỗ như thế nào
- Thơ thất ngôn tứ tuyệt đường luật
- Khi nào hổ con có thể sống độc lập
- Thế nào là hệ số cao nhất
- Diễn thế sinh thái là
- Vẽ hình chiếu vuông góc của vật thể sau
- Ng-html
- 101012 bằng
- Thế nào là mạng điện lắp đặt kiểu nổi
- Lời thề hippocrates
- Chụp phim tư thế worms-breton
- đại từ thay thế
- Vẽ hình chiếu đứng bằng cạnh của vật thể
- Quá trình desamine hóa có thể tạo ra
- Khi nào hổ con có thể sống độc lập
- Các châu lục và đại dương trên thế giới
- Dạng đột biến một nhiễm là
- Biện pháp chống mỏi cơ
- Bổ thể
- độ dài liên kết
- Thiếu nhi thế giới liên hoan
- Bài hát chúa yêu trần thế alleluia
- điện thế nghỉ
- Fecboak
- Một số thể thơ truyền thống
- Sơ đồ cơ thể người
- Công của trọng lực
- Các số nguyên tố là gì
- đặc điểm cơ thể của người tối cổ
- Tỉ lệ cơ thể trẻ em